Assessment of Potential Drug-Drug Interactions and Associated Factors Among Pulmonary Inpatients in a Tertiary Care Hospital: A Cross-Sectional Study [0.03%]
三级医疗机构中肺科住院患者的潜在药物相互作用及影响因素的横断面研究评估
Nim Bahadur Dangi,Hari Prasad Sapkota,Gobinda Kandel et al.
Nim Bahadur Dangi et al.
Background: Potential Drug-drug interactions (pDDIs) are a significant cause of adverse drug events and can compromise treatment outcomes, especially in hospitalized patients who are prescribed multiple medications. Pulmo...
Characteristics and Future Perspectives of Available Electronic Health Record Databases in Japan [0.03%]
日本现有电子健康记录数据库的特点及未来展望
Yi Piao,Yuya Kimijima;PhRMA Japan Medical Affairs Committee Working Group;Michihiko Nakamura,Nobutomo Matsui
Yi Piao
The global use of real-world data (RWD) for drug approval and post-marketing surveillance has increased significantly. During 2023 and 2024, the US Food and Drug Administration issued industry guidance, and the European Medicines Agency rel...
The Long-Term Sequelae and Clinical Workload Resulting from Toxicities of Immune Checkpoint Inhibitor (ICI) Therapy in Patients with Cancer [0.03%]
免疫检查点抑制剂治疗相关毒性的远期后遗症及其对临床工作量的影响
Veera Nurmela,Anni Juntunen,Satu Tiainen et al.
Veera Nurmela et al.
Background: Up to half of cancer patients treated with immune checkpoint inhibitors (ICIs) develop immune-related adverse events (irAEs). However, the long-term consequences of irAEs remain poorly characterized. ...
Treatment Patterns and Healthcare-Related Costs in Patients with Atherosclerotic Cardiovascular Disease: Insights from a Large US Healthcare Insurer [0.03%]
美国一家大型医疗保险公司的心血管疾病患者的治疗模式和医疗相关费用的见解
Joseph L Smith,Laetitia N&#x;Dri,Zhengzheng Jiang et al.
Joseph L Smith et al.
Background and objective: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of death in the USA. We evaluated lipid-lowering therapy (LLT) and the impact of adherence on healthcare costs among patients wit...
Long-Term Antidepressant Use and Dementia Risk: A Propensity Score-Matched Study of Swiss Older Adults, with an Anticholinergic-Specific Analysis [0.03%]
抗抑郁药的长期使用与痴呆风险的关系：基于瑞士老年人群倾向分值匹配研究的抗胆碱作用特异性分析
Melanie A Amrein,Michael P Hengartner,Markus Näpflin et al.
Melanie A Amrein et al.
Background: Antidepressants are widely prescribed, with increasing use among older adults. However, evidence on their association with dementia remains inconsistent. ...
Real-World Evidence for Drug Value Assessment in China: Learning from International Experiences [0.03%]
中国药物价值评估的现实证据：借鉴国际经验
Abraham G Hartzema,Adel Gehchan,Jennifer D Guo et al.
Abraham G Hartzema et al.
In China, the national medical insurance system has undergone rapid development over the past two decades. The National Healthcare Security Administration was established to manage the growing healthcare expenditure. Since then, this admini...
Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort [0.03%]
奥法木单抗在复发性多发性硬化症中的有效性和安全性：一项多中心队列研究中治疗初治患者和转换患者的对比研究
Vincenzo Mangialardi,Giuseppe Macchitella,Rita Vitobello et al.
Vincenzo Mangialardi et al.
Background: Ofatumumab (OFA) is a fully human anti-CD20 monoclonal antibody approved for the treatment of relapsing multiple sclerosis (RMS). Real-world data on its effectiveness and safety remain limited. ...
Safety and Effectiveness of Intravenous Belimumab in Patients with Systemic Lupus Erythematosus in South Korea: A Multicentre, Observational, Real-World Study [0.03%]
韩国系统性红斑狼疮患者静脉注射贝利尤单抗的疗效和安全性：一项多中心、观察性、真实世界的研究
Sang-Bae Yoo,Jung-Eun Cho,Da-Jung Baek et al.
Sang-Bae Yoo et al.
Background: In South Korea, belimumab is indicated for patients with systemic lupus erythematosus (SLE), including paediatric patients aged ≥ 5 years, and for adults with lupus nephritis, based on clinical trial evidence...
From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer [0.03%]
从基因组检测到奥拉帕利治疗：BRCA突变型转移性去势抵抗性前列腺癌的现实世界应用及疗效
Dianne Bosch,Kim J M van der Velden,Aart Beeker et al.
Dianne Bosch et al.
Background: In November 2020, olaparib became the first approved poly adenosine diphosphate (ADP)-ribose polymerase inhibitor (PARPi) for metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations (BRC...
Patient‑Reported Satisfaction in Relapsing-Remitting Multiple Sclerosis: Advantages of At‑Home Self‑Administered Subcutaneous Ofatumumab Versus Other High‑Efficacy Therapies [0.03%]
复发缓解型多发性硬化患者的报告满意度：居家自给皮下注射Ofatumumab与其它高效治疗方案的优势
Francesco Pastore,Emanuela Domenicone,Patrizia DellOro et al.
Francesco Pastore et al.
Background: Multiple sclerosis is an immune-mediated disorder characterized by demyelination and neurodegeneration. Disease-modifying therapies are available with a range of mechanisms of action, efficacies, safety profil...